Advancing Therapies Where Metabolism Begins
Our HDV™ platform supports a growing pipeline of therapies designed to overcome limitations in today’s most-used metabolic treatments—addressing unmet patient needs in diabetes, obesity, and fatty liver disease with targeted precision.
.avif)
Our Pipeline
Diasome’s research pipeline is focused on advancing therapies across three key areas:
HDV Mealtime Insulin
Type 1 DiabetesType 2 DiabetesS.C. InjectablePhase 2PHase 2BPhase 3Best-in-class Mealtime Insulin
By directing insulin to the liver, HDV restores physiologic glucose regulation at mealtime. This liver-targeted approach reduces hypoglycemia, improves post-prandial predictability and expands the therapeutic window of rapid-acting insulin.
Next anticipated milestone:
- Ph 2b OPTI-2 trial top line data, Q1 2026
- Mechanism of Action top line data, Q1 2026
HDV-Serotonin Program
Type 2 DiabetesORALPhase 2PHase 2BPhase 3Addressing Insulin Resistance in Type 2 Diabetes
A novel, first-in-class oral therapy that replaces declining or deficient portal-hepatic serotonin levels, enabling hepatic utilization of insulin.
Next anticipated milestone:
- Anticipated tox study completion: Early Q4 2025
- IND filing anticipated Q1 2026
HDV-GLP-1 and GLP-1/GIP Program
Type 2 DiabetesS.C. InjectablePhase 2PHase 2BPhase 3Using HDV targeted incretins to access the Gut-Liver-Brain axis
Intestinal-derived GLP-1 plays an important role in several metabolic processes including brain-mediated satiety signaling and appetite regulation. By targeting GLP-1 to the portal vein we improve efficacy in fat, glucose and weight endpoints, while mitigating off-target side effects.
Next anticipated milestone:
- IND filing anticipated Q4 2025